Canopy Growth Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Canopy Growth Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2019 | 12.76M | Jun 1, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 269.00M | May 30, 2025 |
| FY2025 | Mar 31, 2024 | 297.15M | May 30, 2025 |
| FY2025 | Mar 31, 2023 | 333.25M | May 30, 2025 |
| FY2023 | Dec 31, 2022 | 104.03M | Jun 22, 2023 |
| FY2023 | Sep 30, 2022 | 105.42M | Jun 22, 2023 |
| FY2023 | Jun 30, 2022 | 105.92M | Jun 22, 2023 |
| FY2024 | Mar 31, 2022 | 475.70M | May 30, 2024 |
| FY2021 | Mar 31, 2021 | 148.44M | Jun 1, 2021 |
| FY2021 | Dec 31, 2020 | 152.53M | Jun 1, 2021 |
| FY2021 | Sep 30, 2020 | 135.27M | Jun 1, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 79.51M | May 30, 2025 |
| FY2025 | Mar 31, 2024 | 80.88M | May 30, 2025 |
| FY2025 | Mar 31, 2023 | (63.53M) | May 30, 2025 |
| FY2023 | Dec 31, 2022 | (95,000) | Jun 22, 2023 |
| FY2023 | Sep 30, 2022 | (7.96M) | Jun 22, 2023 |
| FY2023 | Jun 30, 2022 | (5.59M) | Jun 22, 2023 |
| FY2024 | Mar 31, 2022 | (187.41M) | May 30, 2024 |
| FY2021 | Mar 31, 2021 | 9.80M | Jun 1, 2021 |
| FY2021 | Dec 31, 2020 | 24.59M | Jun 1, 2021 |
| FY2021 | Sep 30, 2020 | 26.08M | Jun 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (598.12M) | May 30, 2025 |
| FY2025 | Mar 31, 2024 | (657.27M) | May 30, 2025 |
| FY2025 | Mar 31, 2023 | (3.28B) | May 30, 2025 |
| FY2023 | Dec 31, 2022 | (259.47M) | Jun 22, 2023 |
| FY2023 | Sep 30, 2022 | (292.17M) | Jun 22, 2023 |
| FY2023 | Jun 30, 2022 | (2.09B) | Jun 22, 2023 |
| FY2024 | Mar 31, 2022 | (310.04M) | May 30, 2024 |
| FY2021 | Mar 31, 2021 | (699.98M) | Jun 1, 2021 |
| FY2021 | Dec 31, 2020 | (904.38M) | Jun 1, 2021 |
| FY2021 | Sep 30, 2020 | (32.06M) | Jun 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (117.14M) | May 30, 2025 |
| FY2025 | Mar 31, 2024 | (228.71M) | May 30, 2025 |
| FY2025 | Mar 31, 2023 | (2.63B) | May 30, 2025 |
| FY2023 | Dec 31, 2022 | (151.42M) | Jun 22, 2023 |
| FY2023 | Sep 30, 2022 | (249.75M) | Jun 22, 2023 |
| FY2023 | Jun 30, 2022 | (1.84B) | Jun 22, 2023 |
| FY2024 | Mar 31, 2022 | (1.02B) | May 30, 2024 |
| FY2023 | Mar 31, 2021 | (1.24B) | Jun 22, 2023 |
| FY2022 | Mar 31, 2020 | (1.67B) | May 31, 2022 |
| FY2021 | Mar 31, 2019 | (637.45M) | Jun 1, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 2.74M | May 30, 2025 |
| FY2025 | Mar 31, 2024 | 4.61M | May 30, 2025 |
| FY2025 | Mar 31, 2023 | 21.72M | May 30, 2025 |
| FY2024 | Mar 31, 2022 | 32.26M | May 30, 2024 |
| FY2023 | Mar 31, 2021 | 57.58M | Jun 22, 2023 |
| FY2022 | Mar 31, 2020 | 61.81M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | 15.24M | Jun 1, 2021 |
| FY2020 | Mar 31, 2018 | 2.05M | Jun 1, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 169.63M | May 30, 2025 |
| FY2025 | Mar 31, 2024 | 229.43M | May 30, 2025 |
| FY2025 | Mar 31, 2023 | 342.52M | May 30, 2025 |
| FY2024 | Mar 31, 2022 | 415.45M | May 30, 2024 |
| FY2023 | Mar 31, 2021 | 575.39M | Jun 22, 2023 |
| FY2022 | Mar 31, 2020 | 693.74M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | 392.25M | Jun 1, 2021 |
| FY2020 | Mar 31, 2018 | 103.48M | Jun 1, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (165.75M) | May 30, 2025 |
| FY2025 | Mar 31, 2024 | (281.95M) | May 30, 2025 |
| FY2025 | Mar 31, 2023 | (557.55M) | May 30, 2025 |
| FY2023 | Dec 31, 2022 | (417.81M) | Jun 22, 2023 |
| FY2023 | Sep 30, 2022 | (273.92M) | Jun 22, 2023 |
| FY2023 | Jun 30, 2022 | (140.52M) | Jun 22, 2023 |
| FY2024 | Mar 31, 2022 | (545.81M) | May 30, 2024 |
| FY2023 | Mar 31, 2021 | (465.73M) | Jun 22, 2023 |
| FY2022 | Mar 31, 2020 | (772.64M) | May 31, 2022 |
| FY2021 | Mar 31, 2019 | (535.03M) | Jun 1, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 10.81M | May 30, 2025 |
| FY2025 | Mar 31, 2024 | 3.45M | May 30, 2025 |
| FY2025 | Mar 31, 2023 | 9.11M | May 30, 2025 |
| FY2024 | Mar 31, 2022 | 36.68M | May 30, 2024 |
| FY2023 | Mar 31, 2021 | 164.50M | Jun 22, 2023 |
| FY2022 | Mar 31, 2020 | 704.94M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | 644.46M | Jun 1, 2021 |
| FY2020 | Mar 31, 2018 | 175.96M | Jun 1, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 917.70M | May 30, 2025 |
| FY2025 | Mar 31, 2024 | 1.30B | May 30, 2025 |
| FY2024 | Mar 31, 2023 | 2.44B | May 30, 2024 |
| FY2023 | Dec 31, 2022 | 2.94B | Jun 22, 2023 |
| FY2023 | Sep 30, 2022 | 3.32B | Jun 22, 2023 |
| FY2023 | Jun 30, 2022 | 3.50B | Jun 22, 2023 |
| FY2023 | Mar 31, 2022 | 5.61B | Jun 22, 2023 |
| FY2022 | Mar 31, 2021 | 6.82B | May 31, 2022 |
| FY2021 | Mar 31, 2020 | 6.86B | Jun 1, 2021 |
| FY2020 | Mar 31, 2019 | 8.57B | Jun 1, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 430.49M | May 30, 2025 |
| FY2025 | Mar 31, 2024 | 799.82M | May 30, 2025 |
| FY2024 | Mar 31, 2023 | 1.68B | May 30, 2024 |
| FY2023 | Dec 31, 2022 | 1.58B | Jun 22, 2023 |
| FY2023 | Sep 30, 2022 | 1.75B | Jun 22, 2023 |
| FY2023 | Jun 30, 2022 | 1.83B | Jun 22, 2023 |
| FY2023 | Mar 31, 2022 | 1.98B | Jun 22, 2023 |
| FY2022 | Mar 31, 2021 | 3.20B | May 31, 2022 |
| FY2021 | Mar 31, 2020 | 1.68B | Jun 1, 2021 |
| FY2020 | Mar 31, 2019 | 1.49B | Jun 1, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 487.21M | May 30, 2025 |
| FY2025 | Mar 31, 2024 | 500.37M | May 30, 2025 |
| FY2024 | Mar 31, 2023 | 758.44M | May 30, 2024 |
| FY2023 | Dec 31, 2022 | 1.35B | Jun 22, 2023 |
| FY2023 | Sep 30, 2022 | 1.55B | Jun 22, 2023 |
| FY2023 | Jun 30, 2022 | 1.64B | Jun 22, 2023 |
| FY2023 | Mar 31, 2022 | 3.58B | Jun 22, 2023 |
| FY2022 | Mar 31, 2021 | 3.48B | May 31, 2022 |
| FY2021 | Mar 31, 2020 | 4.89B | Jun 1, 2021 |
| FY2020 | Mar 31, 2019 | 6.78B | Jun 1, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 46.04M | May 30, 2025 |
| FY2025 | Mar 31, 2024 | 43.24M | May 30, 2025 |
| FY2025 | Mar 31, 2023 | 85.56M | May 30, 2025 |
| FY2023 | Dec 31, 2022 | 84.68M | Jun 22, 2023 |
| FY2023 | Sep 30, 2022 | 79.11M | Jun 22, 2023 |
| FY2024 | Mar 31, 2022 | 1.81B | May 30, 2024 |
| FY2023 | Mar 31, 2021 | 1.89B | Jun 22, 2023 |
| FY2022 | Mar 31, 2020 | 1.95B | May 31, 2022 |
| FY2021 | Mar 31, 2019 | 1.49B | Jun 1, 2021 |
| FY2020 | Mar 31, 2018 | 277.45M | Jun 1, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (10.93B) | May 30, 2025 |
| FY2025 | Mar 31, 2024 | (10.33B) | May 30, 2025 |
| FY2024 | Mar 31, 2023 | (9.67B) | May 30, 2024 |
| FY2023 | Dec 31, 2022 | (9.03B) | Jun 22, 2023 |
| FY2023 | Sep 30, 2022 | (8.77B) | Jun 22, 2023 |
| FY2023 | Jun 30, 2022 | (8.47B) | Jun 22, 2023 |
| FY2023 | Mar 31, 2022 | (6.38B) | Jun 22, 2023 |
| FY2022 | Mar 31, 2021 | (6.07B) | May 31, 2022 |
| FY2021 | Mar 31, 2020 | (4.32B) | Jun 1, 2021 |
| FY2020 | Mar 31, 2019 | (835.12M) | Jun 1, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 113.81M | May 30, 2025 |
| FY2025 | Mar 31, 2024 | 170.30M | May 30, 2025 |
| FY2024 | Mar 31, 2023 | 667.69M | May 30, 2024 |
| FY2023 | Mar 31, 2022 | 776.01M | Jun 22, 2023 |
| FY2022 | Mar 31, 2021 | 1.15B | May 31, 2022 |
| FY2021 | Mar 31, 2020 | 1.30B | Jun 1, 2021 |
| FY2020 | Mar 31, 2019 | 2.48B | Jun 1, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | 1.31B | Jun 22, 2023 |
| FY2023 | Mar 31, 2022 | 1.50B | Jun 22, 2023 |
| FY2022 | Mar 31, 2021 | 1.58B | May 31, 2022 |
| FY2021 | Mar 31, 2020 | 465.42M | Jun 1, 2021 |
| FY2020 | Mar 31, 2019 | 945.98M | Jun 1, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (5) | May 30, 2025 |
| FY2025 | Mar 31, 2024 | (8) | May 30, 2025 |
| FY2025 | Mar 31, 2023 | (70) | May 30, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Jun 22, 2023 |
| FY2023 | Sep 30, 2022 | 0 | Jun 22, 2023 |
| FY2023 | Jun 30, 2022 | (5) | Jun 22, 2023 |
| FY2024 | Mar 31, 2022 | (7) | May 30, 2024 |
| FY2023 | Mar 31, 2021 | (4) | Jun 22, 2023 |
| FY2021 | Mar 31, 2020 | (3) | Jun 1, 2021 |
| FY2021 | Dec 31, 2019 | 0 | Jun 1, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (5) | May 30, 2025 |
| FY2025 | Mar 31, 2024 | (8) | May 30, 2025 |
| FY2025 | Mar 31, 2023 | (70) | May 30, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Jun 22, 2023 |
| FY2023 | Sep 30, 2022 | 0 | Jun 22, 2023 |
| FY2023 | Jun 30, 2022 | (5) | Jun 22, 2023 |
| FY2024 | Mar 31, 2022 | (7) | May 30, 2024 |
| FY2023 | Mar 31, 2021 | (4) | Jun 22, 2023 |
| FY2021 | Mar 31, 2020 | (3) | Jun 1, 2021 |
| FY2021 | Dec 31, 2019 | 0 | Jun 1, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 183.87M | May 30, 2025 |
| FY2025 | Mar 31, 2024 | 91.12M | May 30, 2025 |
| FY2024 | Mar 31, 2023 | 51.73M | May 30, 2024 |